Sequenom to Sponsor Workshop Introducing Prenatal Diagnostics at AMP 2007 Annual Meeting

Sequenom, Inc. (NASDAQ: SQNM) today announced that the Company will sponsor a corporate workshop introducing its noninvasive prenatal technology at the Association for Molecular Pathology 2007 (AMP 2007) Annual Meeting being held at The Hyatt Regency Century Plaza Hotel in Los Angeles. The two-hour workshop is scheduled for Wednesday, November 7, 2007, beginning at 11:00 a.m. Pacific time. Sequenom will also host an exhibition booth at the AMP 2007 meeting that will include products and information related to its genomics analysis business featuring its MassARRAY® platform. Sequenom also announced it will market its exclusively licensed nucleic acid-based technology under the brand "SEQureDx™, A Sequenom Technology.” The Company is developing and plans to commercialize molecular diagnostic tests based on this technology for the screening and detection of prenatal disorders and disease, such as Rhesus D incompatibility, Fetal xy -- a gender test designed to assess the prenatal risk of inherited disorders such as Congenital Adrenal Hyperplasia, Fragile X, Hemophilia, and a test for common anueploidies, such as Downs syndrome. The Sequenom workshop, "Introducing the Dawn of a New Technology: Noninvasive Prenatal Diagnostics,” hosted by Steve Owings, Vice President Commercial Development, Prenatal Diagnostics at Sequenom, will include the following presentations: Fetal Nucleic Acids in Maternal Plasma as a New Platform for Noninvasive Prenatal Diagnosis, presented by Dr. Dennis Lo, Professor of Chemical Pathology, Li Ka Shing, Professor of Medicine and Director of the Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong Extraction & Enrichment Methods for Fetal DNA, presented by Dr. Markus Sprenger-Haussels, Associate Director R&D, Diagnostic Sample Preparation & Stabilization of Qiagen, Hilden, Germany Research to Practice: User Experience, presented by Leonard H. Kellner, President and CSO, Lenetix Medical Screening Laboratory and Senior Associate of the Department of Obstetrics and Gynecology, Albert Einstein College of Medicine of Yeshiva University, Lenetix Medical Screening Laboratory, Mineola, New York MassARRAY Technology: Past and Future Applications in Genetic Testing, presented by Dr. Christine Eng, Associate Professor of Molecular and Human Genetics, Director of DNA Diagnostics Laboratory, and Director of the Storage Disorders Clinic at Baylor University, Houston Strategies for Successful Noninvasive Prenatal Testing: Fetal Identifiers and Workshop Summary, presented by Dr. Betty Dragon, Senior Vice President of Research and Development at Sequenom "The AMP 2007 workshop provides the ideal forum to introduce our breakthrough Fetal Nucleic Acid Technology and our SEQureDx brand to the key stakeholders involved in clinical molecular diagnostics,” said Mr. Owings. "Our workshop features top industry thought leaders and experts discussing developments in maternal fetal medicine and noninvasive prenatal tests that we believe will create a new standard in prenatal care for women, their families and their healthcare providers. "We are building a menu of prenatal tests with this technology, and expect the near-term commercial introduction of the first laboratory developed test (home brew) developed by our partner Lenetix Medical Screening Laboratory, to detect Rhesus D incompatibility. During the workshop we also plan to provide an update on our work toward introducing a groundbreaking strategy for noninvasive detection of Down syndrome,” he added. A copy of Sequenom’s workshop brochure is available on the home page of the Sequenom Web site (www.sequenom.com) and online registration for this seminar is available at http://www.AMP.org/2007/ or by contacting Lynn Clement at lclement@sequenom.com. The Sequenom workshop is being held during the AMP Corporate Workshop Day, Wednesday, November 7th, the first of the four-day AMP event. AMP 2007 includes poster sessions, workshops and plenary sessions covering major areas of clinical molecular diagnostics, including hematopathology, infectious diseases, inherited genetic diseases, solid tumors and technical topics. About The Association for Molecular Pathology The Association of Molecular Pathology (AMP) is committed to the advancement of clinical molecular diagnostic and prognostic medicine through education and training of practitioners, physicians, laboratory and industrial scientists, and health care professionals involved in patient care and management. AMP supports the development of new technologies in molecular biology to be used in laboratory medicine, including diagnosis, treatment and prognosis of genetic disorders, cancer, infectious diseases, identity and histocompatibility. More information about AMP 2007 is available at www.amp.org/2007. About Sequenom Sequenom is committed to providing the best genetic analysis products that translate genomic science into superior solutions for biomedical research, livestock and agricultural applications, molecular medicine, and non-invasive prenatal testing. Sequenom’s proprietary MassARRAY system is a high-performance nucleic acid analysis platform that efficiently and precisely measures the amount of genetic target material and variations therein. The system is able to deliver reliable and specific data from complex biological samples and from genetic target material that is only available in trace amounts. Sequenom has exclusively licensed intellectual property rights for the development and commercialization of non-invasive prenatal genetic tests for use with the MassARRAY system and other platforms. Sequenom®, SEQureDxTM, and MassARRAY® are trademarks of Sequenom, Inc. Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the workshop, the Company’s development and plans to commercialize molecular diagnostic tests, building a portfolio of prenatal applications, the Company’s planned noninvasive prenatal tests and their impact on standard of care, the Company’s expectation of near-term commercial introduction of a test to detect Rhesus D incompatibility, and the Company’s plans and work toward introducing a groundbreaking strategy for the noninvasive detection of Down syndrome, are forward-looking statements within the meaning of the "safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with the Company’s operating performance, demand for and market acceptance of the Company’s products, services, and technologies, new technology and product development and commercialization particularly for new technologies such as molecular diagnostics, and particularly non-invasive prenatal diagnostics, reliance upon the collaborative efforts of other parties, research and development progress, competition, government regulation, obtaining or maintaining regulatory approvals, and other risks detailed from time to time in the Company’s SEC (U.S. Securities and Exchange Commission) filings, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2006 and other documents subsequently filed with or furnished to the SEC. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.